Global Inhalation CDMO Market Anticipated to Undergo Strong Growth Through 2030
The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.
What Are the Projections for Inhalation CDMO Market Size and CAGR During 2026-2030?
The inhalation cdmo market size has grown strongly in recent years. It will grow from $2.2 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising prevalence of asthma and copd, increasing demand for inhalation therapies, growth of biologics and specialized drug formulations, advancements in formulation technologies, increasing outsourcing by pharmaceutical companies.
The inhalation cdmo market size is expected to see strong growth in the next few years. It will grow to $3.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to expansion of digital and smart inhalers, growth in personalized medicine and precision therapy, increased investment in inhalation cdmo infrastructure, rising adoption of advanced manufacturing technologies, increasing collaborations between biotech firms and cdmos. Major trends in the forecast period include personalized inhalation therapy development, advanced formulation and drug delivery techniques, regulatory compliance and quality assurance enhancements, contract manufacturing expansion for small and medium-sized firms, integration of smart inhalers and digital health monitoring.
Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
Which Factors Are Driving Growth in the Inhalation CDMO Market?
The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, in December 2023, according to the National Library of Medicine, a US-based medical library, the global number of chronic obstructive pulmonary disease (COPD) cases among those 25 and older is projected to rise by 23% by 2050, reaching nearly 600 million. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.
What Are the Emerging Segments in the Inhalation CDMO Market?
The inhalation cdmo market covered in this report is segmented –
1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs
2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs
3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers
4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices
What Are the Most Prominent Trends Impacting the Inhalation CDMO Market?
Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart's Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.
Who Are the Leading Companies in the Inhalation CDMO Industry by Revenue?
Major companies operating in the inhalation cdmo market are Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Copley Scientific, Cambrex Corporation, AptarGroup Inc.
Get the full inhalation cdmo market report here:
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
Which Region Is Projected to Account for the Largest Share of the Inhalation CDMO Market?
North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2025. The regions covered in the inhalation cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment